Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has provided an announcement.
Pharmaron Beijing Co., Ltd. has announced the current composition of its board of directors, which includes executive, non-executive, independent non-executive and employee representative directors, led by chairman Dr. Lou Boliang. The company has also detailed the structure of its four key board committees—Audit, Remuneration and Appraisal, Nomination, and Strategy—clarifying chairperson and member roles among directors, a move that underscores its corporate governance framework and may provide investors and other stakeholders with greater transparency into oversight and strategic decision-making.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a China-based company listed in Hong Kong that operates in the pharmaceutical and life sciences sector. The company provides research, development and related services to the pharmaceutical industry, positioning itself as a key player in supporting drug discovery and development for global and domestic clients.
Average Trading Volume: 5,297,525
Technical Sentiment Signal: Buy
Current Market Cap: HK$51.92B
Find detailed analytics on 3759 stock on TipRanks’ Stock Analysis page.